tiprankstipranks

David Mott Insider Profile

11 Followers
David Mott, Ten Percent Owner at Oruka Therapeutics, holds 1.43M shares in Ardelyx (Ticker: ARDX), holds 50.47K shares in Novavax (Ticker: NVAX), holds 598.29K shares in Mersana Therapeutics (Ticker: MRSN). Most recently, David Mott Bought ― shares of Ardelyx on Nov 14, 2024 for an estimated value of 995.15K.
tipranks
David Mott

David Mott
Oruka Therapeutics (ORKA)
Ten Percent Owner

Ranked #5,182 out of 99,335 Corporate Insiders

Profitable Transactions

34%
22 out of 65 Profitable Transactions

Average Return

+10.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$856M
65.74%
21.36%
7.95%
1.44%
3.51% Others
A breakdown of David Mott's holdings

Insider Roles

Elastic
(ESTC)
Ten Percent Owner
Mirum Pharmaceuticals
(MIRM)
Ten Percent Owner
Adaptimmune Therapeutics
(ADAP)
Director
Trevi Therapeutics
(TRVI)
Ten Percent Owner
+12 other positions
Roles that David Mott holds in companies

Most Profitable Insider Trade

Stock:
Achaogen
(AKAOQ)
Rating:Informative Buy
Date:Jun 07, 2016 - Jun 07, 2017
Return:+423.70%
The most profitable trade made by David Mott

David Mott's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Oruka Therapeutics
Feb 27, 2018
Ten Percent Owner
Informative Sell
730.10K
$0.00
Adaptimmune Therapeutics
Jan 28, 2020
Director
Informative Buy
4.95M
$68.05M
AVEO
AVEO Pharma
Apr 08, 2019
Informative Buy
4.96M
$378.66M
AKAOQ
Achaogen
Dec 19, 2016
Informative Buy
6.75M
$117.88K
CASC
Cascadian Therapeutics
Mar 13, 2018
Uninformative Sell
$0.00
Regulus
May 09, 2019
Ten Percent Owner
Informative Buy
1.23M
$2.87M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Buy
$575.25K
Mersana Therapeutics
Jan 04, 2024
Director
Uninformative Buy
$1.33M
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$6.11M
SURF
Surface Oncology
Apr 23, 2018
Informative Buy
2.00M
$3.54M
MULE
Mulesoft Inc
May 09, 2018
Uninformative Sell
$0.00
Elastic
Oct 10, 2018
Ten Percent Owner
Uninformative Buy
$562.79M
~NITE
Nightstar Therapeutics Limited
Jun 07, 2019
Uninformative Sell
169.89M
$0.00
Genocea Biosciences
Jun 25, 2019
Ten Percent Owner
Informative Buy
10.00M
$108.39K
Trevi Therapeutics
May 13, 2019
Ten Percent Owner
Uninformative Buy
$12.29M
Mirum Pharmaceuticals
Jul 24, 2019
Ten Percent Owner
Uninformative Buy
$182.90M
Enliven Therapeutics
Feb 23, 2022
Director
Informative Buy
219.67K
$5.83M
Novavax
Jun 14, 2024
Director
Uninformative Buy
105.79K
$406.79K
Ardelyx
Nov 14, 2024
Director
Informative Buy
995.15K
$7.01M
TRACON Pharmaceuticals
Mar 27, 2018
Ten Percent Owner
Informative Buy
1.91M
$103.98K
EPZM
Epizyme
Aug 16, 2022
Uninformative Sell
$0.00
Box
Jan 22, 2015
Ten Percent Owner
Informative Buy
$5.40M
TSRO
Tesaro
Jan 22, 2019
Uninformative Sell
782.79M
$0.00
~DERM
Dermira
Oct 08, 2014
Informative Buy
1.11M
$65.68M
LOXO
Loxo Oncology
Aug 06, 2014
Informative Buy
3.00M
$419.91M
~HIVE
Aerohive Networks
Apr 03, 2014
Uninformative Buy
$20.75M
CRCM
Care
Nov 08, 2017
Uninformative Buy
$33.88M
MM
Millennial Media
Oct 30, 2012
Informative Sell
21.47M
$14.34M
ROKA
Sorrento Tech Inc
Jul 22, 2014
Informative Buy
4.60M
$2.09M
Workday
Apr 11, 2013
Ten Percent Owner
Uninformative Buy
$303.80K
CLVSQ
Clovis Oncology
Jun 05, 2013
Uninformative Sell
$8.63
OMTH
Omthera
List of latest transactions for each holding click on a transaction to see David Mott's performance on stock

David Mott insider profile FAQ

What is the percentage of profitable transactions made by David Mott?
The percentage of profitable transactions made by David Mott is 34%.
    What is the average return per transaction made by David Mott?
    The average return per transaction made by David Mott is 10.80%.
      What stocks does David Mott hold?
      David Mott holds: ORKA, ADAP, AVEO, AKAOQ, CASC, RGLS, APPN, MRSN, SYBX, SURF, MULE, ESTC, ~NITE, GNCAQ, TRVI, MIRM, ELVN, NVAX, ARDX, TCON, EPZM, BOX, TSRO, ~DERM, LOXO, ~HIVE, CRCM, MM, ROKA, WDAY, CLVSQ, OMTH stocks.
        What was David Mott’s latest transaction?
        David Mott latest transaction was an Informative Buy of $995.15K.
          What was David Mott's most profitable transaction?
          David Mott’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
            What is David Mott's role in Oruka Therapeutics?
            David Mott's role in Oruka Therapeutics is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.